Vascular endothelial growth factor-121 localised protein delivery - GenVec

Drug Profile

Vascular endothelial growth factor-121 localised protein delivery - GenVec

Alternative Names: AdGVVEGF121.10NH; BIOBYPASS; BIOBYPASS® angiogen; BIOBYPASS®-CAD; CI 1023; Vascular endothelial growth factor gene therapy - GenVec

Latest Information Update: 29 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenVec
  • Developer Cordis Corporation; GenVec
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Ischaemic heart disorders
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
  • 04 Oct 2015 Cordis Corporation has been acquired by Cardinal Health
  • 14 Mar 2005 Phase-II clinical trials in Ischaemic heart disorders in Europe (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top